Letteratura scientifica selezionata sul tema "Psychiatric comorbidities"
Cita una fonte nei formati APA, MLA, Chicago, Harvard e in molti altri stili
Consulta la lista di attuali articoli, libri, tesi, atti di convegni e altre fonti scientifiche attinenti al tema "Psychiatric comorbidities".
Accanto a ogni fonte nell'elenco di riferimenti c'è un pulsante "Aggiungi alla bibliografia". Premilo e genereremo automaticamente la citazione bibliografica dell'opera scelta nello stile citazionale di cui hai bisogno: APA, MLA, Harvard, Chicago, Vancouver ecc.
Puoi anche scaricare il testo completo della pubblicazione scientifica nel formato .pdf e leggere online l'abstract (il sommario) dell'opera se è presente nei metadati.
Articoli di riviste sul tema "Psychiatric comorbidities"
1
Şahin Cankurtaran, Eylem. "Psychiatric comorbidities in spondyloartrities". Ulusal Romatoloji Dergisi 12, n. 2 (1 dicembre 2020): 67–72. http://dx.doi.org/10.4274/raed.galenos.2020.s109.
Testo completo
2
Reardon, Claudia L. "Psychiatric Comorbidities in Sports". Neurologic Clinics 35, n. 3 (agosto 2017): 537–46. http://dx.doi.org/10.1016/j.ncl.2017.03.007.
Testo completo
3
Josephson, Colin B., e Nathalie Jetté. "Psychiatric comorbidities in epilepsy". International Review of Psychiatry 29, n. 5 (6 luglio 2017): 409–24. http://dx.doi.org/10.1080/09540261.2017.1302412.
Testo completo
4
Baskin, S. "Psychiatric comorbidities in migraine". Journal of the Neurological Sciences 357 (ottobre 2015): e457. http://dx.doi.org/10.1016/j.jns.2015.09.145.
Testo completo
5
Buckley, P. F., B. J. Miller, D. S. Lehrer e D. J. Castle. "Psychiatric Comorbidities and Schizophrenia". Schizophrenia Bulletin 35, n. 2 (14 novembre 2008): 383–402. http://dx.doi.org/10.1093/schbul/sbn135.
Testo completo
6
Araz Altay, Mengühan, Işık Görker, Begüm Demirci Şipka, Leyla Bozatlı e Tuğçe Ataş. "Attention Deficit Hyperactivity Disorder and Psychiatric Comorbidities". Eurasian Journal of Family Medicine 9, n. 1 (31 marzo 2020): 27–34. http://dx.doi.org/10.33880/ejfm.2020090104.
Testo completoAbstract (sommario):
Aim: This study aims to obtain current information on the clinical features of attention deficit hyperactivity disorder cases, comorbid psychiatric disorders and psychiatric drug use. Methods: All patients between the ages of 6 and 18 years who were admitted to our outpatient clinic and diagnosed with attention deficit hyperactivity disorder were included in the study. The files of the patients were examined and their demographic characteristics, symptoms, psychiatric diagnoses and drug profiles were recorded. The pattern of the psychiatric disorders accompanied by attention deficit hyperactivity disorder cases and the differences according to age and gender were analyzed. The differences were determined in patients with psychiatric comorbidity compared to those without. Result: The mean age of the 777 patients included in the study was 11.1±2.94 and 76.6% were boys. 60.9% of attention deficit hyperactivity disorder patients had comorbid psychiatric disorders. The most common psychiatric comorbidities were specific learning disability (23.6%), oppositional defiant disorder (12.9%) and conduct disorder (12.1%). There was no difference between the genders in terms of the incidence of psychiatric comorbidities. The rate of psychiatric comorbidity was significantly higher in adolescents than in children. A psychotropic medication was used in 86.4% of the cases and psychotropic polypharmacy was present in 31.5%. The rate of polypharmacy was significantly higher in the group with psychiatric comorbidity. Conclusion: Attention deficit hyperactivity disorder is frequently accompanied by other psychiatric disorders and the psychiatric comorbidity leads to a more complicated clinical profile. Approximately one-third of attention deficit hyperactivity disorder patients have psychiatric polypharmacy and these patients should be carefully monitored. Primary care physicians who are frequently confronted with attention deficit hyperactivity disorder cases should be careful about psychiatric comorbidities. Keywords: Child psychiatry, attention deficit hyperactivity disorder, mental disorders, Family practice
7
Silić, Ante. "Somatic Comorbidities in Psychiatric Patients". Cardiologia Croatica 12, n. 5-6 (giugno 2017): 275–81. http://dx.doi.org/10.15836/ccar2017.275.
Testo completo
8
Stanculete, M. F., e D. L. Dumitrascu. "Psychiatric Comorbidities in IBS Patients". Journal of Psychosomatic Research 85 (giugno 2016): 81. http://dx.doi.org/10.1016/j.jpsychores.2016.03.201.
Testo completo
9
Im-Bolter, Nancie, e Nancy J. Cohen. "Language Impairment and Psychiatric Comorbidities". Pediatric Clinics of North America 54, n. 3 (giugno 2007): 525–42. http://dx.doi.org/10.1016/j.pcl.2007.02.008.
Testo completo
10
Kao, Chi-Han, Shuu-Jiun Wang, Chia-Fen Tsai, Shih-Pin Chen, Yen-Feng Wang e Jong-Ling Fuh. "Psychiatric comorbidities in allodynic migraineurs". Cephalalgia 34, n. 3 (18 settembre 2013): 211–18. http://dx.doi.org/10.1177/0333102413505238.
Testo completoAbstract (sommario):
Objectives To evaluate the prevalence and the association of psychological disturbance in migraine patients with allodynia. Methods We recruited 434 migraine patients from an outpatient clinic. The participants completed three self-administered questionnaires, including a headache questionnaire, an allodynia symptoms checklist, and the Hospital Anxiety and Depression Scale (HADS). Results Among the migraineurs, 48.4% participants reported allodynia. The HADS total score (15.5 ± 7.8 vs. 13.7 ± 8.5, p = 0.022) and anxiety subscore (9.1 ± 4.5 vs. 7.6 ± 4.7, p = 0.001) were higher in migraineurs with allodynia than in those without allodynia. The anxiety subscore in patients with moderate to severe allodynia, mild allodynia, and no allodynia were 10.0 ± 4.5, 8.4 ± 4.3, and 7.6 ± 4.7 ( p < 0.001, by one-way analysis of variance). Among patients with moderate to severe allodynia, there was a trend of higher depression subscore (7.1 ± 4.0, p = 0.059) than those with no (6.1 ± 4.4) or mild allodynia (5.8 ± 4.0). In a regression model, the presence of allodynia is an independent risk factor for clinically significant anxiety. Moderate to severe allodynia is an independent risk factor for clinically significant depression. Conclusions In migraineurs, the severity of cutaneous allodynia was associated with their mood status, especially anxiety.
Tesi sul tema "Psychiatric comorbidities"
1
Edvinsson, Dan. "Attention Deficit/Hyperactivity Disorder in Adults : Prevalence, Psychiatric Comorbidities and Long-term Outcome". Doctoral thesis, Uppsala universitet, Psykiatri, Akademiska sjukhuset, 2017. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-327892.
Testo completoAbstract (sommario):
Attention Deficit/Hyperactivity Disorder (ADHD) was originally thought to occur only in children, but is increasingly recognised as causing functional impairment also in adulthood. The overall aim of this thesis was to achieve a comprehensive understanding of ADHD in adulthood. A questionnaire based on the DSM-IV criteria of ADHD, reported childhood symptoms, reading and spelling problems, difficulties and suffering and general assessment of functioning (GAF) was distributed to three samples: the general population (GP), outpatient psychiatry (OPP) and female prison inmates. Symptoms consistent with ADHD were more than three times higher in the OPP sample than in the GP sample (6.6 versus 2.1%). ADHD symptoms and related problems occurred in 50% of the prison inmates. A cohort of 168 patients diagnosed with ADHD in adulthood was interviewed about current ADHD symptoms and psychiatric comorbidity on axis I and II. The lifetime prevalence of psychiatric comorbidity on axis I was 92% and current comorbidity, including autism spectrum disorders and Tourette’s syndrome, was 47%. The sex-specific pattern of the comorbid disor-ders was similar to that in the general population. Forty-six per cent of the patients endorsed the specific criteria for at least one personality disorder. After a mean follow-up of six years, there was remission of adult ADHD in about 30% of the patients, regardless of whether there was ongoing medication or not. There were no differences in function and quality of life, except for global general improvement, which was better in patients currently on medication. The most prevalent long-term side effects of pharmacological treatment with mainly stimulants were decreased appetite, dry mouth, anxiousness/restlessness and an increase in pulse frequency. The discontinuation rate was about 50%: 29% discontinued because of a perceived lack of effect, followed by elevated mood or hypomania (11%). No detectable evidence of tolerance and increased need for dosage over time was observed. To conclude, Symptoms of ADHD is highly overrepresented in OPP and in female inmates compared with the GP. Furthermore, adults diagnosed with ADHD have a high lifetime prevalence of psychiatric comorbidity. Long-term pharmacological treatment with stimulants is safe with relatively mild and tolerable adverse effects. Continued medication, however, is not related to remission.
2
Gomez, Rosalinda, Jennifer Holt e Claire Huynh. "Characteristics of Patients and their Treatments at an Inpatient Facility for Detoxification and Treatment of Chemical Dependence". The University of Arizona, 2005. http://hdl.handle.net/10150/624744.
Testo completoAbstract (sommario):
Class of 2005 AbstractObjectives: The purpose of this study was to determine the demographics of co-morbid disorders and drug abuse characteristics of patients admitted to an inpatient facility for detoxification and treatment of chemical dependency to characterize the treatment programs including the psychiatric medication usage and prescribing patterns and to identify differences between men and women. Methods: Criteria inclusion for admittance included a diagnosis of chemical dependence at Sierra Tucson Behavioral Health Hospital during the time of January through June 2004. Patients were admitted to that were diagnosed with a chemical dependency, identified using a past hospital census. Charts of previously discharged patients were obtained from the medical records department of the institution. Specific variables from each chart were extracted for further analysis utilizing a data form. Results: 285 (170 women and 115) men chemically dependent patients that were admitted during the six-month study period. In this patient population there was a high incidence, 76.84%, of co-morbid psychiatric conditions. The most frequently abused drugs in men were alcohol, nicotine, and cocaine. The most frequently abused drugs in women were alcohol, nicotine, and opiates. Men and women were most frequently placed on a librium based alcohol detoxification program, and secondly a buprenorphine based opiate detoxification program. There was statistical significant improvement in the of Beck Depression Inventory scale (BDI), Beck Hopelessness scale (BHS), and Global Assessment Function (GAF) scores at admit and discharge and a downward trend in Clinical Institute Withdrawal Assessment (CIWA) and Clinical Opiate Withdrawal (COW) scores. Implications: There was a high incidence of co-morbid psychiatric conditions such as depression and anxiety that were present in both genders. In men, Attention Deficit and Hyperactivity Disorder/ Attention Deficit Disorder (ADHD/ADD) was an additional common condition observed, while in women eating disorders were observed. The treatments provided led to an overall improvement in GAF, BDI, BHS, CIWA and COW scores indicating effectiveness of the treatment program.
3
Greenlee, Jessica L. "A CONTEXTUAL APPROACH TO UNDERSTANDING PSYCHIATRIC COMORBIDITIES IN ADOLESCENTS WITH AUTISM SPECTRUM DISORDER: INDIVIDUAL, PEER, AND FAMILY FACTORS". VCU Scholars Compass, 2019. https://scholarscompass.vcu.edu/etd/5745.
Testo completoAbstract (sommario):
Psychiatric comorbidities are common in youth with Autism Spectrum Disorders (ASD) and can have a negative impact on adaptive functioning and quality of life. Research has primarily focused on individual characteristics associated with internalizing problems such as age, intelligence, and social functioning. However, developmental theory supports the notion that individual level factors are necessary but not sufficient to understand the mental health of youth with ASD. Using the Family Ecology Framework as a guide, the purpose of this study was to examine how peer and family contexts are associated with anxiety and depression symptoms of adolescents with ASD. Using data from adolescents with ASD (13-17 years old) and their primary caregivers (N = 166), this study tested a conditional process model in which youths’ social-communication skills were associated with their mental health symptoms indirectly via experiences of peer victimization, with family competence acting as a buffer against the negative impact of peer victimization on anxiety and depression symptoms. Results suggest that the peer context is important when considering the mental health of adolescents with ASD. Specifically, deficits in social-communication skills were associated with higher levels of parent-reported anxiety and depression symptoms through increased adolescent-reports of peer victimization; however, the hypothesized buffering effect of family competence was not statistically significant. Findings from this study suggest the benefits of utilizing developmentally sensitive, contextual approaches when examining psychiatric comorbidities in adolescents with ASD.
4
Försti, A. K. (Anna-Kaisa). "Incidence, mortality, comorbidities, and treatment of bullous pemphigoid in Finland". Doctoral thesis, Oulun yliopisto, 2017. http://urn.fi/urn:isbn:9789526215310.
Testo completoAbstract (sommario):
Abstract Bullous pemphigoid (BP) is an autoimmune skin disease predominantly found in elderly people, which causes blistering of the skin and severe itching. The incidence of BP reported by previous studies has varied greatly between 0.05 and 42.8 per 1 million persons per year. Higher incidences have been reported in Western Europe and the USA, while countries around the Mediterranean have reported lower rates. However, the epidemiology of BP has not previously been studied in any Scandinavian country. The one-year mortality of BP is highly variable with estimates between 11% and 41% worldwide. As for comorbidities, the previous studies have shown that BP is associated with neurological disorders. The aim of this study was to investigate the incidence and mortality of BP in Finland, to assess the treatments used for BP, and the potential contribution of systemic glucocorticoid treatment to the high mortality rate found in BP patients. A further aim was to obtain more specific information about the neurological diseases associated with BP, and to clarify the less studied association with psychiatric disorders. For these purposes, we collected the records of all immunologically confirmed BP patients diagnosed in the Oulu University Hospital between 1985 and 2012, and, for a sub-study III, data for all patients diagnosed with BP in Finnish hospitals between 1987 and 2013. We found that the incidence of BP in Northern Finland has increased over the past two decades to approximately 27 new BP cases per 1 million persons per year. The one-year mortality of BP patients is 17%, and the standardized mortality ratio (SMR) is 7.6. Common comorbidities found in the sample of BP patients were: cardiovascular diseases (76%), neurodegenerative diseases (41%), skin conditions other than BP (37%) and type 2 diabetes (23%). Many neurodegenerative diseases of the central nervous system were associated with BP, as were many psychiatric disorders. The association was strongest between multiple sclerosis (MS) and BP, with MS patients having almost a 6-fold higher risk of BP than controls. The present study reports for the first time the incidence and mortality of BP in Finland, and provides new information about the association between BP and neurological and psychiatric disordersTiivistelmä Rakkulainen pemfigoidi (josta jatkossa käytetään nimitystä pemfigoidi) on autoimmuunisairaus, joka esiintyy yleensä iäkkäillä, ja aiheuttaa ihon rakkulointia ja hankalaa kutinaa. Aiemmissa tutkimuksissa pemfigoidin ilmaantuvuus on vaihdellut 0,05:sta 42,8:aan tapaukseen miljoonaa ihmistä kohden vuodessa. Ilmaantuvuuden on havaittu olevan korkeampi Länsi-Euroopassa, kun taas Välimeren ympäristössä ilmaantuvuus on matalampi. Pemfigoidia sairastavien kuolleisuus vuoden kuluessa diagnoosista vaihtelee noin 11-41%:n välillä. Aiemmat tutkimukset ovat myös osoittaneet, että pemfigoidi liittyy neurologisiin sairauksiin. Pemfigoidin epidemiologiaa ei ole kuitenkaan tutkittu Suomessa tai muissa Pohjoismaissa. Tämän tutkimuksen tarkoituksena oli selvittää pemfigoidin ilmaantuvuus ja kuolleisuus Suomessa, tutkia sen hoitoon käytettyjä lääkkeitä sekä arvioida systeemisen glukokortikoidihoidon osuutta korkeaan kuolleisuuteen. Lisäksi tavoitteena oli saada yksityiskohtaista tietoa pemfigoidiin liittyvistä neurologisista sairauksista ja selvittää lisää aiemmissa tutkimuksissa ristiriitaiseksi jäänyttä yhteyttä psykiatrisiin sairauksiin. Tätä varten keräsimme tiedot kaikista Oulun yliopistollisessa sairaalassa diagnosoiduista, immunologisesti varmennetuista pemfigoiditapauksista vuosilta 1985-2012. Kolmannessa osatyössä käytimme kansallista aineistoa, joka sisälsi kaikkialla Suomessa diagnosoidut pemfigoidia sairastavat potilaat vuosilta 1987-2013. Pemfigoidin ilmaantuvuus kasvoi seuranta-aikana ollen nykyisin Pohjois-Suomessa noin 27 tapausta miljoonaa ihmistä kohden vuodessa. Kuolleisuus vuoden kuluessa diagnoosista oli 17% ja vakioitu kuolleisuussuhde (standardized mortality ratio) 7,6. Yleisiä oheissairauksia pemfigoidia sairastavilla olivat sydän- ja verisuonisairaudet (76%), neurodegeneratiiviset sairaudet (41%), muut ihosairaudet (37%) sekä tyypin 2 diabetes (23%). Tutkimuksessa todettiin, että monet neurogeneratiiviset sairaudet ja monet psykiatriset sairaudet liittyvät pemfigoidiin. Yhteys oli vahvin pesäkekovettumataudin (MS-tauti) ja pemfigoidin välillä, ja MS-tautia sairastavilla riski sairastua pemfigoidiin oli lähes 6-kertainen verrattuna kontrollipotilaisiin. Tämä tutkimus on ensimmäinen, joka raportoi pemfigoidin ilmaantuvuuden ja kuolleisuuden Suomessa. Tutkimus antaa lisäksi uutta tietoa pemfigoidin yhteydestä neurologisiin ja psykiatrisiin sairauksiin
5
Dal, Pizzol Angélica. "Impacto do uso de benzodiazepínicos no nível de ansiedade em pacientes com epilepsia do lobo temporal". reponame:Biblioteca Digital de Teses e Dissertações da UFRGS, 2011. http://hdl.handle.net/10183/37036.
Testo completoAbstract (sommario):
Nesse trabalho estudamos o impacto do uso de benzodiazepínicos prescritos como co-adjuvantes para o controle de crise nos níveis de ansiedade em pacientes com epilepsia do lobo temporal. Estudo de corte transversal com 99 epilépticos. Avaliamos o nível de ansiedade desses pacientes por meio do Inventário de Ansiedade de Beck (BAI) e da Escala de Ansiedade de Hamilton. Dos 99 pacientes, 15 (15.15%) usavam benzodiazepínico (Clobazam/Clonazepam) e 84 (84.84%) não usavam benzodiazepínico para o controle das crises. Em nossa amostra os pacientes que usavam benzodiazepínico eram mais jovens e iniciaram com as crises mais cedo. Além disso, o uso de benzodiazepínico foi mais comum em pacientes com epilepsia refratária (OR=5.6; 95% CI; 1.97-11.06; p=0.047). Esses dados demonstram que o benzodiazepínico foi utilizado para controle de crise em pacientes com epilepsia refratária do lobo temporal. Nesse estudo observamos que ser mulher, ter transtorno de ansiedade ou de humor detectado pela entrevista clínica estruturada para desordens do eixo I do DSM-IVTR (SCID) está associado com altos níveis de ansiedade tanto na escala de BAI quanto na de Hamiltom. No BAI foi detectado altos níveis de ansiedade em pacientes com crises não controladas (OR=4.67; 95% CI 1.97-11.06; p<0.001). Na escala de ansiedade de Hamiltom encontramos altos níveis de ansiedade em pacientes com história familiar psiquiátrica. Não houve diferença estatisticamente significante nos níveis de ansiedade de pacientes que usavam e que não usavam benzodiazepínico cronicamente para o controle da epilepsia, diferente do que esperávamos. É plausível que o uso crônico de benzodiazepínicos possa induzir tolerância ao efeito ansiolítico desses fármacos em epilepsia. Estudos adicionais são necessários para definir melhores estratégias para o tratamento de transtornos de ansiedade em epilepsia.In this study we evaluate the anxiety levels in patients with temporal lobe epilepsy whether using or not a benzodiazepine for seizure control. We performed a cross-sectional study with 99 patients diagnosed with temporal lobe epilepsy that whether were using or not a benzodiazepine (clobazam or clonazepam) for seizure control. We evaluated the anxiety level of patients using as tools the Beck Anxiety Inventory (BAI) and the Hamilton Anxiety Scale (HAMA). Of the 99 patients, 15 (15.15%) used a benzodiazepine (Clobazam/Clonazepam) and 84 (84.84%) did not use a benzodiazepine for seizure control. In our sample, patients using a benzodiazepine were younger and had seizures early in life. Additionally, the use of a benzodiazepine was more frequent in patients with refractory epilepsy (OR =5.6, 95% CI 1.97-11.06; p=0.047). These data demonstrate the a benzodiazepine was utilized for seizure control in patients with temporal lobe refractory epilepsy. We identified that female sex patients with anxiety disorder or mood disorders detected by SCID demonstrate high anxiety levels measured both with BAI as well as with HAMA. High anxiety levels were detected with the use of BAI in patients with uncontrolled seizures (OR=4.67; 95% CI 1.97-11.06; p<0.001). With the use of Hamiltom we identified high anxiety levels in patients with a positive psychiatric family history. There was no statically significant difference in anxiety levels among patients utilizing or not not a benzodiazepine for seizure control, differently from what we expected. It is plausible that chronic use of benzodiazepines can induce tolerance to the anxiolytic effect of these drugs in epilepsy. Additional studies are needed to define better strategies for treatment of anxiety disorders in epilepsy.
6
Silva, Júnior Estácio Amaro. "Comorbidades psiquiátricas associadas com transtornos de ansiedade em uma amostra de crianças e adolescentes". reponame:Biblioteca Digital de Teses e Dissertações da UFRGS, 2010. http://hdl.handle.net/10183/30940.
Testo completoAbstract (sommario):
Introdução: Os transtornos de ansiedade na infância e adolescência são prevalentes e geralmente se mantêm até a vida adulta. Podem também ser considerados como fator de risco para o desenvolvimento de outros transtornos psiquiátricos. Portanto, a avaliação, o diagnóstico e o tratamento da ansiedade nesta faixa etária, assim como a detecção de comorbidades associadas, têm uma importância significativa para o alívio do sofrimento e para a prevenção de transtornos mentais em futuras etapas do ciclo vital. Objetivos: Avaliar, em uma amostra comunitária de crianças e adolescentes, a presença de comorbidades nos distintos transtornos de ansiedade em comparação ao grupo controle. Métodos: Em um delineamento de caso-controle, entre agosto de 2008 e dezembro de 2009 foram avaliadas, sucessivamente, 242 crianças e adolescentes pertencentes a escolas estaduais que estão dentro da área de abrangência da Unidade Básica de Saúde do Hospital de Clínicas de Porto Alegre (HCPA). A triagem realizada nas escolas faz parte de um projeto de pesquisa no qual foram aplicados instrumentos de avaliação de ansiedade e outros sintomas psiquiátricos com o objetivo de averiguar possíveis casos (ansiosos) e controles, para um amplo estudo sobre transtornos de ansiedade na infância e adolescência. Os indivíduos selecionados, através da triagem escolar, foram posteriormente avaliados através do K-SADS-PL (Schedule for Affective Disorders and Schizophrenia for School-Age Children – Present and Lifetime Version Diagnostic Interview), aplicado aos participantes da pesquisa, juntamente com seus pais, por psiquiatras treinados. Resultados: A amostra final foi composta por 138 casos e 104 controles. Entre os casos, 95 (68,8%) preencheram critérios para diagnóstico de ansiedade generalizada (TAG), 57 (41,3%) para transtorno de ansiedade social (TAS), 49 (35,5%) para transtorno de ansiedade de separação (TASep) e nove (6,5%) preencheram os critérios diagnósticos para transtorno de pânico (TP). Os ansiosos apresentaram alta taxa de comorbidade, ao longo da vida, estatisticamente significativa em comparação ao grupo controle, entre os transtornos de ansiedade: transtorno de ansiedade de separação com fobia específica - FE (51%) e TAG (59,2%); transtorno de ansiedade generalizada com TAS (36,8%), FE (52,6%) e transtorno do estresse pós-traumático - TEPT (8,5%); transtorno de ansiedade social com FE (59,6%) e TAG (61,4%). Também apresentaram mais comorbidade com depressão: com TAG (29,3%) e com TAS (30,9%), e enurese com TASep (22,4%). Conclusão: Houve, na amostra comunitária, uma alta prevalência de transtornos de ansiedade, principalmente transtorno de ansiedade generalizada, transtorno de ansiedade social e transtorno de ansiedade de separação. Evidenciou-se maior comorbidade com os demais transtornos de ansiedade, depressão e enurese entre os ansiosos em comparação ao grupo controle. Observou-se que possuir a comorbidade aumenta o risco de ter o desfecho (transtorno de ansiedade). É importante a realização de pesquisas similares com um maior número amostral, e de estudos caso-controle em amostras clínicas, para confirmação dos nossos resultados.Introduction: Anxiety disorders in childhood and adolescence are prevalent, often remain until adulthood and may also be considered as a risk factor for developing other psychiatric disorders. Therefore, assessment, diagnosis and treatment of anxiety in this age group as well as the detection of comorbidities have a significant importance for the relief of suffering and the prevention of mental disorders in future stages of the lifecycle. Objectives: To evaluate the presence of comorbidities in the different anxiety disorders compared to controls in a community sample of children and adolescents. Methods: 242 children and adolescents were evaluated successively in the state schools which are within the area covered by the primary care unit of Hospital de Clinicas de Porto Alegre (HCPA) in a randomized case-control study, between August 2008 and December 2009. The screening conducted in schools is part of a research project in which instruments were used to evaluate anxiety and other psychiatric symptoms in order to investigate possible cases (anxious) and controls for an extensive study of anxiety disorders in childhood and adolescence. Those selected through the school screening, were subsequently evaluated using the K-SADS-PL (Schedule for Affective Disorders and Schizophrenia for School-Age Children - Present and Lifetime Version Diagnostic Interview), applied to the research participants, along with their parents by trained psychiatrists. Results: The final sample included 138 cases and 104 controls. Among cases, 95 (68.8%) met diagnostic criteria for generalized anxiety disorder (GAD), 57 (41.3%) for social anxiety disorder (SAD), 49 (35.5%) for separation anxiety disorder (SepAD) and nine (6.5%) met the diagnostic criteria for panic disorder (PD). The forward had a high rate of comorbidity in lifetime, statistically significant compared to the control group, among the anxiety disorders: separation anxiety disorder with specific phobia - SP (51%) and GAD (59.2%); generalized anxiety disorder with SAD (36.8%), SP (52.6%) disorder and posttraumatic stress disorder - PTSD (8.5%), social anxiety disorder with PS (59.6%) and GAD (61.4%). There was also more comorbidity between depression with GAD (29.3%) and SAD (30.9%) and enuresis with SepAD (22.4%). Conclusion: There was a high prevalence of anxiety disorders, particularly generalized anxiety disorder, social anxiety disorder and separation anxiety disorder in the community sample. There has been a higher comorbidity with other anxiety disorders, depression and enuresis among anxious compared to control group and it has been observed that having the comorbidity increases the risk of the outcome (anxiety disorder). It is extremely relevant and important to conduct similar research with a larger sample and case-control studies in clinical samples to confirm the results.
7
Penna, Ana Cláudia. "O impacto do exercício físico aeróbico sobre comorbidade psiquiátrica, impulsividade e comportamento de jogo, em portadores de transtorno do jogo: um estudo randomizado e controlado". Universidade de São Paulo, 2018. http://www.teses.usp.br/teses/disponiveis/5/5142/tde-07112018-115129/.
Testo completoAbstract (sommario):
Introdução: o Transtorno do jogo (TJ), anteriormente classificado como transtorno do controle do impulso, está classificado hoje, no DSM-5, entre as dependências, sendo a primeira vez que se reconhece outro comportamento (apostar), além do uso de substância, como uma dependência. Evidências apontam melhoras relevantes no funcionamento físico e psicológico propiciadas pela atividade física. É desconhecido, entretanto, se um programa de exercícios físicos pode ser útil no tratamento do transtorno do jogo (TJ), devido à falta de estudos, ao tamanho reduzido das amostras e à falta de grupo controle. Objetivo: abordar essas lacunas empíricas através da realização de um ensaio clínico controlado e randomizado com um programa de exercício físico aeróbico comparado a um grupo controle ativo (alongamento), em acréscimo ao tratamento usual para TJ, para avaliação dos efeitos do exercício aeróbico nas comorbidades psiquiátricas, na impulsividade e no comportamento de jogo. Metodologia: 59 participantes com diagnóstico confirmado de TJ em início de tratamento foram designados, aleatoriamente, para uma, de duas possibilidades: grupo experimental (GE, n=32), com oito semanas de exercício físico, duas sessões de 50 minutos, cada (10 minutos de alongamento, mais 40 minutos de exercício aeróbico com intensidade moderada a intensa, ou seja, 70 a 85% da frequência cardíaca máxima estimada para a idade); ou grupo controle (GC, n=27), com sessões de alongamento de 50 minutos, duas vezes por semana, pelo mesmo período. Teste de Cooper e monitores de frequência cardíaca foram utilizados para garantir que os participantes do GE cumprissem a frequência cardíaca alvo. Avaliadores cegos ao tipo de intervenção designada analisaram os participantes, antes e depois da intervenção. O tratamento com psicoterapia e uso de medicações psiquiátricas, durante a intervenção, foram registrados para o controle estatístico. Resultados: foram observadas reduções significativas na frequência de depressão e nas comorbidades psiquiátricas em geral, em ambos os grupos, após a intervenção. O GE apresentou uma redução mais significativa das comorbidades psiquiátricas, quando comparado ao GC (razão de chances = 3,3; p=0,036), está diferença permaneceu significativa quando foi avaliado o subgrupo de indivíduos que realizaram apenas a intervenção física sem psicoterapia simultânea (n=42; razão de chances = 4,8; p=0,030). Não houve diferenças significativas entre os grupos, no uso de medicação psiquiátrica. Ambos os grupos também melhoraram, em relação à impulsividade avaliada em testagem neuropsicológica (controle inibitório e planejamento), mas não na impulsividade avaliada por autorrelato. As variáveis relacionadas ao jogo, ou seja, às apostas, prejuízo de socialização, desgaste emocional, e financeiro, e a \"fissura\" sofreram todas redução significativa ao final da intervenção, porém sem diferença entre GE e GC. Conclusão: um programa de exercício aeróbico tem um efeito significativo na redução das comorbidades psiquiátricas associadas em portadores de TJ, em tratamento. Este efeito mostrou-se independente da psicoterapia e da medicação. Portanto, o exercício físico pode ser um complemento valioso para o tratamento do TJ, por ser acessível, além de ser uma alternativa aos medicamentos psiquiátricos, ajudando as pessoas que sofrem com TJ a viverem com uma melhor qualidade de vidaIntroduction: The Gambling Disorder (GD), formerly classified as the impulse control disorder, is classified today in the DSM-5 among the dependencies, being this the first time other behavior (to bet) is recognized beyond the use of substances, as a dependency. Evidences have indicated relevant improvement in the physical and psychological performance propitiated by the physical activity. Nevertheless it is unknown if a physical exercise program may be useful in the Gambling Disorder (GD) treatment, due to the lack of studies, the reduced size of the samples and the lack of control group. Objective: Approaching these empiric shorcomings through a random and controlled clinic analysis with an aerobic physical exercise program compared to an active control group (stretching) besides the usual treatment to GD, to evaluate the effects of the aerobic exercises in the psychiatric comorbidity, in the impulsiveness and in the game behavior. Methodology: Fifty-nine participants with a confirmed diagnostic in GD in the beginning of the treatment were designated randomly for one of the two possibilities : experimental group (GE, n=32), eight weeks of physical exercises, with two sections of fifty minutes each (10 minutes of stretching, plus 40 minutes of aerobic exercises with moderate to intense intensity, i.e. from 70 to 85% of the maximum cardio frequency estimated to the age; or the controll group (GC, n=27), fifty minutes stretching sessions twice a week during the same period. Cooper\'s Test and cardio-frequency monitors were used to guarantee that the participants of the GE fulfilled the cardio frequency target. Evaluators blind to the designated intervention analyzed the participants before and after the intervention. The treatment with psychotherapy and the use of psychiatric medicines during the intervention were registered for statistical control. Results: Significant reductions in the frequency of depression and the psychiatric comorbidity were observed after the intervention, generally in both groups. GE presented a more expressive reduction in the psychiatric comorbidities when compared to GC (odds ration = 3,3 : p=0,036), this difference remained meaningful when the subgroup which held only the physical intervention, without simultaneous psychotherapy was evaluated (n=42 : odds ratio = 4,8 : p=0,030). There were no meaningful differences between the groups in the use of psychiatric medication. Both groups also improved in relation to the assessed impulsiveness in neuropsychological test (planning and inhibitory control), but not in the impulsivity evaluated in self-report. The variable related to game, i.e. bets, socialization detriment, emotional and financial weakening and chink have suffered all the meaningful reductions at the end of the intervention, but without difference between GE and GC. Conclusion: An aerobic exercise program has meaningful effect in the reduction of the psychiatric comorbidities associated to GD bearer in treatment, this effect happened independently of the psychotherapy and medication. Therefore, physical exercise may be a valuable complement to GD treatment because it is approachable, besides being an alternative to the psychiatric medicaments, helping people who suffer with GD to live with a better quality of life
8
Narvaez, Joana Corrêa de Magalhães. "O amor nos tempos do crack : psicodinâmica, comportamento, biologia e uma proposição de estadiamento funcional". reponame:Biblioteca Digital de Teses e Dissertações da UFRGS, 2014. http://hdl.handle.net/10183/110189.
Testo completoAbstract (sommario):
Introdução: Estudos destacam a prevalência crescente do crack (forma fumada de apresentação da cocaína, com ação psicoestimulante, com impacto nos neurônios e neurotransmissores cerebrais dopaminérgicos) no Brasil, em contraponto aos limitados resultados terapêuticos. Dados recentes apontam que cerca de 1% dos jovens já fizeram uso na vida de crack. A expressão clínica de um funcionamento piorado pode se dar através de marcadores de externalização social, como violência, impulsividade e comportamentos autodestrutivos. A literatura demonstra associação do crack com comportamentos sexuais de risco, violência e contravenções. Para além dos indicadores de impacto na sociedade, os sujeitos com histórico de uso de crack, podem apresentar prejuízo nos múltiplos domínios vitais, como: qualidade de vida, capacidade para o trabalho, estudo e manutenção satisfatória dos vínculos sociais. Além de tratarem-se usualmente de usuários de múltiplas substâncias e com importantes índices de associação com comorbidades psiquiátricas. É por isso que a literatura tem ampliado os estudos no que se refere à qualidade de vida dos usuários, apoio social e comorbidades associadas, tratando-se de indicadores de resultados terapêuticos que impactam no ingresso do uso, manutenção, abstinência posterior e prognóstico. No entanto, ainda são escassos os estudos no campo do abuso de substâncias, sobretudo em relação à usuários de crack. Ademais, um crescente corpo de evidências sugere que o uso de crack tem consequências sistêmicas generalizadas, mas pouca atenção tem sido dada à sua fisiopatologia. Neste sentido, o entendimento do funcionamento social e biológico dos usuários pode contribuir para alavancar terapêuticas mais efetivas e direcionadas as distintas etapas e características dos usuários. Neste sentido, esta tese objetiva: Avaliar a funcionalidade social, exposição à risco, comorbidades e biomarcadores em usuários de crack, culminando na proposição de um modelo de estadiamento. Apresentamos aqui três modelos metodológicos: O primeiro, de base populacional que avaliou aspectos sobre a funcionalidade social (qualidade de vida, produtividade, estrutura e apoio parental, adesão à prática religiosa, acesso e adesão ao tratamento), exposição à risco (práticas sexuais, episódios de agressão e porte de armas), além de comorbidades (psiquiátricas e com demais substâncias) em sujeitos de 18 a 24 anos com histórico de uso de crack em relação à população em geral. O segundo estudo diz respeito à avaliação de biomarcadores, se deu através de estudo de comparação de grupos com cinquenta e três pacientes ambulatoriais usuários de crack, combinados com cinquenta controles. O terceiro estudo pressupõe uma revisão da literatura para proposição de um modelo de estadiamento incluindo as variáveis verificadas nos demais estudos. Os resultados do estudo de base populacional indicam que os sujeitos com histórico de uso de crack demonstram prejuízo, em relação à população geral, nas múltiplas dimensões da funcionalidade social e qualidade de vida, em destaque a saúde geral, física, significativas mesmo controlando para uso na vida de cocaína, além da saúde emocional, mental e da percepção de dor. Do ponto de vista relacional evidenciam diferenças no que se refere estrutura da família nuclear no lar, na qual mães se mostram mais presentes e pais mais ausentes em relação à população em geral. Há indícios de impacto expresso na produtividade funcional em termos de escolaridade e na relação com instituições sociais, como o sistema de saúde. O histórico de uso de crack está associado com prejuízos no que tange a gestão de autocuidado e de exposição à risco, demonstrando maiores índices, em relação à população geral, de comportamento agressivo, uso de armas e práticas sexuais de risco. No que se refere aos biomarcadores e marcadores inflamatórios, evidenciou-se um aumento significativo no BDNF, IL- 1V, TNF- W e IL- 10 em usuários, sendo que não há diferenças no dano oxidativo, em relação aos controles. O estudo destes aspectos serviu de base para proposição de um modelo de estadiamento do uso do crack tendo como base a funcionalidade social dos usuários. Como considerações finais, ao que tudo indica, usuários de crack apresentam especificidades desde a constituição parental no lar à maior vulnerabilidade psicossocial. Revela-se um caráter de descontinuidade e irregularidade na adaptação à demanda funcional inicial, que se reedita na circularidade do sujeito pelas diferentes instâncias sociais, em códigos de autopreservação, e em comportamentos de externalização, estando eles mais expostos a condutas de risco e comorbidades associadas, além do prejuízo expresso também em termos de biomarcadores. O discernimento de tal aspecto pode ter impacto clínico e na elaboração de políticas públicas combativas não somente ao crack, mas às vulnerabilidades sociais preliminares e associadas à droga.Introduction: Studies highlight the rising prevalence of crack cocaine (form of cocaine that are smoked, with psychostimulant action, affect dopaminergic brain neurotransmitters and neurons) users in Brazil, in contrast to the limited therapeutic results. Recent data indicate that approximately 1% of young people have already used crack cocaine in lifetime. The clinical expression of a worsened functioning may be through outsourcing social markers such as violence, impulsivity and selfdestructive behaviors. The literature demonstrates association of crack cocaine with risky sexual behavior, and violence misdemeanors. In addition to indicators of impact on society, the subjects with a history of crack cocaine use may experience impairments in multiple vital areas such as: quality of life, ability to work, study and satisfactory maintenance of social bonds, and most often they are multiple substances users and have significant rates of psychiatric comorbidities associations. That is why the literature has extended the studies of the quality of life of users, social support and associated comorbidities, the therapeutic outcomes indicators that impact the inflow of use, maintenance, withdrawal and subsequent prognosis. However, there are still few studies in the field of substance abuse, especially in relation to crack cocaine users. Moreover, a growing body of evidence suggests that crack cocaine use has widespread systemic consequences, but little attention has been given to its pathophysiology. In this sense, an understanding of the social and biological functioning of the users can help to leverage more effective targeted therapies linked to different stages and characteristics of users. This thesis aims to evaluate the social functioning, exposure to risk, comorbidities and biomarkers in crack cocaine users, culminating in proposing a model of staging. Here are three methodological models: The first, a population-based study that assessed aspects of social functioning (quality of life, productivity, structure and parental support, adherence to religious practice, access and adherence to treatment), exposure to risk (sexual practices, episodes of aggression and possession of weapons), and comorbidity (psychiatric and other substances) in subjects between 18 to 24 yearsold with a history of crack cocaine use, compared to the general population. The second study focus on evaluation of biomarkers through a comparative study between grups with fifty-three outpatients crack cocaine users, combined with fifty controls. The third study presupposes a literature review, to propose a model of staging including variables verified in other studies. The results of the populationbased study indicate that subjects with a history of crack cocaine use (compare with the general population) show a loss in the multiple dimensions of social functioning and quality of life, highlighted the general health, physical, in significant even after controlling for use in the life of cocaine, plus the emotional, mental and perception of pain. The relational dimension revealed differences regarding the structure of the nuclear family in the home, in which mothers are more present and fathers more absent in relation to the general population. There are indications of impact, expressed in functional productivity in terms of scholarity and relationship with social institutions, such as the health system. The history of crack cocaine use is associated with damage in terms of self-care management and risk exposure, demonstrating highest rates of aggressive behavior, use of weapons and risky sexual practices, when compared with the general population. With regard to biomarkers and inflammatory markers, revealed a significant increase in BDNF, IL- 1V, TNF- W and IL- 10 in users, with no differences in oxidative damage, compared to controls. The study of these aspects formed the basis for proposing a model of staging of the use of crack cocaine, based on the social functionality of users. As conclusion, it seems that crack cocaine users have specificities from the parental constitution of the home to greater psychosocial vulnerability. There is a character discontinuity and irregularity in the initial adaptation to functional demands, which replays in the circularity of the subject by the various social environments, codes of selfpreservation, and externalizing behaviors, while they are more exposed to risk behaviors and associated comorbidities besides the loss also expressed in terms of biomarkers. The insight of that aspect may have clinical and developmental impact, not only the crack cocaine combative public policy, but also to combat social precrack cocaine vulnerabilities.
9
Faller, Sibele. "Resultados acerca do uso de substâncias psicoativas no Brasil a partir de estudos multicêntricos". reponame:Biblioteca Digital de Teses e Dissertações da UFRGS, 2015. http://hdl.handle.net/10183/148849.
Testo completoAbstract (sommario):
Objetivos: Essa tese apresentou dados de dois estudos pioneiros no país, considerando a avaliação de usuários de SPAs em tratamento e a associação entre marcadores de gravidade em usuários de crack. Método: Os dados são oriundos de dois estudos multicêntricos. Estudo 1: delineamento transversal. Foram avaliados adultos (>18 anos) em uso recente de álcool ou drogas (n=600), provenientes de locais públicos de tratamento (ambulatórios e internações). Os instrumentos aplicados foram: ASI6, WHOQOL-BREF e MINI. Estudo 2: delineamento longitudinal. Foram avaliados adultos (>18 anos) com diagnóstico de abuso ou dependência de crack (n=1100), provenientes de locais públicos de tratamento (ambulatórios e internações). Os instrumentos aplicados foram: ASI6, MINI, PCC e EGD. Resultados: No Artigo 1, os escores do ASI6 foram comparados entre usuários que nunca haviam recebido tratamento para uso de substâncias psicoativas (n=265, 36,1%) e aqueles que já haviam sido tratados em uma ou mais ocasiões (n=470, 63,9%). Essas análises revelaram diferenças significativas entre os grupos em relação ao uso de drogas, transtornos psiquiátricos, problemas legais e familiares/sociais (p0.05). No artigo 2, foi realizada uma análise de regressão entre os escores do ASI-6 e os domínios do WHOQOL-BREF, que foram examinados usando variáveis que apresentaram significância estatística na análise de correlação. Todos os problemas relacionados às diferentes áreas da vida apresentaram correlações negativas com os domínios de qualidade de vida. No artigo 3, foi desenvolvido um modelo de equações estruturais, que apresentou um bom ajuste. A gravidade do uso de crack mediou a relação entre transtorno de conduta e violência. A associação direta entre a gravidade do uso de crack e comportamento violento (=.67) foi mais baixa do que a associação entre a gravidade do uso de álcool e comportamento violento (=.68). O Transtorno de conduta afeta a gravidade do uso de crack (= .17), que impacta na violência, mediada pelo uso de álcool. Considerações finais: Em relação ao primeiro artigo apresentado, os achados evidenciam a complexidade presente no tratamento dos indivíduos com problemas relacionados ao uso nocivo de substâncias, mostrando variáveis que influenciam na gestão dos pacientes e no planejamento de intervenções. O segundo artigo verificou que a diminuição da qualidade de vida em pacientes alcoolistas não estava diretamente vinculada à gravidade do uso de álcool, mas sim a problemas comuns encontrados em amostras equivalentes, como questões médicas. O terceiro artigo desenvolveu um modelo de equações estruturais com o objetivo de explicar parte das associações entre trauma, gravidade do uso de crack, transtorno de conduta, outras comorbidades psiquiátricas, uso de álcool e violência, variável esta posta como desfecho. A associação direta entre a gravidade do uso de crack e comportamento violento foi menor do que entre a gravidade do uso de álcool e comportamento violento. O transtorno de conduta afetou a gravidade do uso de crack, variável esta que impacta na violência mediada pelo álcool. Espera-se que esses estudos contribuam para um planejamento de intervenções terapêuticas mais adequadas e para o desenvolvimento de estratégias de prevenção e políticas públicas que protejam esse indivíduo, contemplando os vários aspectos de sua vida.Introduction: This thesis presented data from two pioneering studies in the country regarding the evaluation of substance users in treatment and the association between markers of severity in crack users. Objectives: The aims were to identify characteristics of drug users under treatment, with an emphasis on severity of problems, drug that motivated seeking treatment, and quality of life in alcoholics, as well the relations between traumatic events, psychiatric comorbidity, severity of crack use and violence in crack users. Method: Data were obtained from two multicenter studies. Study 1: cross-sectional design. Adults (> 18) of a public treatment system, with recent use of alcohol or drugs (n = 600) were evaluated. The instruments applied were: ASI6, WHOQOL e MINI. Study 2: longitudinal design. Adults (> 18) from a public treatment system, diagnosed with crack abuse or dependence (n = 1100) were evaluated. The instruments applied were: ASI6, MINI, PCC and EGD. Results: Paper 1: The SS-Rs were compared between users who had never received treatment for psychoactive substance abuse (n=265, 36.1%) and those who had already been treated for substance abuse in one or more occasions (n=470, 63.9%). This analysis revealed significant differences between the groups in the drug, psychiatric symptoms, legal, and family/social problems areas (p0.05). Paper 2: The regression analyses between the ASI-6 summary scores and the WHOQOL-BREF domains analyzed variables that presented statistical significance in the correlation analysis. All problems related to the different areas of life showed negative correlations with QoL domains. Paper 3: The path model corresponding to the study constructs indicated a good fit to the data. Severity of crack use mediated the relationship between conduct disorder and violence. The direct association between the severity of crack cocaine use and violent behavior (estimate =.67) was lower than the association between the severity of alcohol use and violent behavior (estimate =.68). Conduct disorder affects the severity of crack use (estimate = .17), which impacts violence mediated by alcohol. Conclusions: The findings highlight the complexity involved in the treatment for individuals with problems related to harmful substances use, showing variables that influence in interventions planning. We found that the decreased quality of life in alcoholics was not directly linked to the severity of alcohol use, but to the common problems found in similar samples, like medical issues. According to the structural equation model, conduct disorder affected the severity of crack use, which impacted violence mediated by alcohol. It is expected that these studies contribute to shape appropriate therapeutic interventions planning and the development of public policies and prevention strategies that protect individuals, considering the various aspects of life.
10
Waldmann-Villaume, Sébastien Kahn Jean-Pierre. "Dépendance et psychiatrie Etude sur 2 ans d'une population de 47 patients /". [S.l.] : [s.n.], 2009. http://www.scd.uhp-nancy.fr/docnum/SCDMED_T_2009_WALDMANN_VILLAUME_SEBASTIEN.pdf.
Testo completoLibri sul tema "Psychiatric comorbidities"
1
Mazzone, Luigi, e Benedetto Vitiello, a cura di. Psychiatric Symptoms and Comorbidities in Autism Spectrum Disorder. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-29695-1.
Testo completo
2
Buckley, Peter F., David J. Castle e Rachel Upthegrove. Schizophrenia and Psychiatric Comorbidities: Recognition Management. Oxford University Press, 2020.
Cerca il testo completo
3
Yarnell, Stephanie, e Ellen Edens. Prevalence and Severity of Psychiatric Comorbidities. A cura di Ish P. Bhalla, Rajesh R. Tampi, Vinod H. Srihari e Michael E. Hochman. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190625085.003.0020.
Testo completoAbstract (sommario):
Chapter 20—The Prevalence and Severity of Psychiatric Comorbidities provides a summary of a landmark study in epidemiology, the The National Comorbidity Survey Replication (NCS-R). This chapter study sought to answer some fundamental questions. How common are comorbid psychiatric conditions? What are the prevalence and severity rates for comorbid anxiety, mood, impulse control, and substance use disorders? Starting with these questions, this chapter describes the basics of the study, including funding, study location, who was studied, how many patients, study design, study intervention, follow-up, endpoints, results, and criticism and limitations. The chapter briefly reviews other relevant studies and information, discusses implications, and concludes with a relevant clinical case.
4
Beckman, Nancy J., e Marie B. Tobin. Psychiatric Comorbidities in Chronic Pain Syndromes. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190271787.003.0033.
Testo completoAbstract (sommario):
Psychiatric comorbidities are common in patients with chronic pain syndromes. Depression, anxiety, insomnia, somatic symptom disorder, substance use disorders, personality disorders, and problematic coping strategies present unique treatment challenges to pain medicine specialists. Patients with these comorbidities tend to have poorer response to treatment, higher rates of complications, and greater pain-related suffering. To reduce stigma, providers are encouraged to define pain as both a sensory and emotional experience. This intimate connection implies that optimal pain treatment requires concurrent attention to psychosocial well-being. Overlapping biological and psychologic mechanisms in the development of chronic pain and psychiatric disorders may contribute to the high rates of comorbidity. Methods for quickly identifying psychiatric disorders within busy clinic settings and brief interventions that pain specialists can deliver are described. Finally, indications for referral to specialty mental health and the benefits of multidisciplinary treatment, which can include psychiatric medications and evidence-based psychologic treatments, such as cognitive-behavioral therapy, are discussed.
5
Vitiello, Benedetto, e Luigi Mazzone. Psychiatric Symptoms and Comorbidities in Autism Spectrum Disorder. Springer, 2018.
Cerca il testo completo
6
Halmi, Katherine A. Psychological Comorbidities of Eating Disorders. A cura di W. Stewart Agras e Athena Robinson. Oxford University Press, 2017. http://dx.doi.org/10.1093/oxfordhb/9780190620998.013.13.
Testo completoAbstract (sommario):
Psychological comorbidity of eating disorders may be conceptualized in varying facets including psychiatric diagnosis, specific behaviors, traits, affect regulation, and cognitive characteristics. Although the Diagnostic and Statistical Manual, fifth edition (DSM-5) modified some criteria for psychiatric diagnoses, these modifications should have little effect over the previous rates of DSM-IV comorbidities and thus do not necessitate repeat large sample comorbidity studies. This chapter presents facets of psychological comorbidities of the three major eating disorders: anorexia nervosa (AN), bulimia nervosa (BN), and binge eating disorder (BED). The most comprehensive comorbid psychiatric diagnosis study from the US national comorbidity survey replication revealed at least one lifetime comorbid psychiatric DSM-IV disorder was present in 56.2% AN, 94.5% BN, and 78.9% BED. Affect regulation, negative affect, perfectionism, cognitive-behavioral flexibility, and impulse control are common comorbid features present in these disorders.
7
Haag, Anja, Clarissa Lin Yasuda, Britta Wandschneider e Silvia Bonelli, a cura di. Cognitive and Psychiatric Comorbidities in Epilepsy: Insights from Neuroimaging Research. Frontiers Media SA, 2020. http://dx.doi.org/10.3389/978-2-88963-898-7.
Testo completo
8
Soffer, Jocelyn, e Harold W. Goforth. Endocrine Comorbidities in Persons with HIV. A cura di Mary Ann Cohen, Jack M. Gorman, Jeffrey M. Jacobson, Paul Volberding e Scott Letendre. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199392742.003.0045.
Testo completoAbstract (sommario):
A wide range of endocrine abnormalities commonly accompany and complicate HIV infection, many of which have implications for psychiatrists and other mental health professionals working with this population. Such abnormalities include adrenal insufficiency, hypercortisolism, hyperthyroidism, hypothyroidism, hypogonadism, decreased bone mineral density, and bone disease. Endocrinopathies are great mimickers of psychiatric disorders, manifesting in some cases as disturbances of mood, sleep, appetite, thought process, energy level, or general sense of well-being. Understanding the intricate and complex relationships between immunological, endocrinological, and psychological systems is important to improve recognition and treatment of reversible endocrinopathies, diminish suffering, and enhance quality of life and longevity in persons with HIV and AIDS. This chapter will present an overview of HIV-associated changes in the function of the hypothalamic–pituitary axes, adrenal glands, thyroid gland, gonads, and bone and mineral metabolism, and consider the psychosocial implications of such endocrinopathies.
9
Hirschtritt, Matthew E., Marc N. Potenza e Linda C. Mayes. Impulsivity and Co-occurring Psychiatric Disorders. A cura di Jon E. Grant e Marc N. Potenza. Oxford University Press, 2012. http://dx.doi.org/10.1093/oxfordhb/9780195389715.013.0033.
Testo completoAbstract (sommario):
Dual diagnosis, the co-occurrence of substance abuse and another psychiatric disorder, is common. There is evidence to suggest that impulsivity may serve as a common substrate for these comorbidities, despite behavioral and biochemical differences between disorders. This chapter describes common neurobiological and behavioral findings between individuals with high impulsivity and those with dual diagnosis. Specifically, we focus on the co-occurrence of substance abuse with schizophrenia, eating disorders, attention-deficit/hyperactivity disorder, antisocial and borderline personality disorders, and bipolar disorder. For each type of dual diagnosis, we review literature that provides empirical evidence for the presence of impulsivity and treatment recommendations. In this context, we propose a “bottom-up” conceptualization, in which clusters of co-occurring phenotypes are used to formulate diagnostic and clinical plans; such an approach may produce more homogeneous diagnostic groups than exist in the current system. Further, a bottom-up approach may reveal that dual-diagnosis disorders represent distinct groups that share a common factor of impulsivity.
10
Fenton, Lynne, Brian Rothberg, Laura Strom, Allison M. Heru e Mesha-Gay Brown. Integrative Care Model for Neurology and Psychiatry. A cura di Robert E. Feinstein, Joseph V. Connelly e Marilyn S. Feinstein. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780190276201.003.0019.
Testo completoAbstract (sommario):
Nonepileptic seizures resemble epileptic seizures but lack epileptiform activity on an electroencephalogram and presumably have psychopathologic origins. Psychiatric comorbidities are common, and effective management requires psychiatric treatment. Unfortunately, many patients fear that seeing a psychiatrist implies their episodes are not being taken seriously and that their neurologist might perceive them as producing their symptoms willfully. Patients might feel abandoned if their neurologist refers them to a psychiatrist and indicates that they no longer need to be seen by the neurologist. Consequently, patients often resist undergoing psychiatric evaluation. To help address this problem our team piloted a program integrating psychiatric and neurologic approaches, placing a therapeutic treatment group within the neurology outpatient department. This chapter reviews the clinical features of non-epileptic seizures, including diagnosis and treatment, and presents our team’s integrated treatment approach.
Capitoli di libri sul tema "Psychiatric comorbidities"
1
Donigan, Jessica M., e Alexa B. Kimball. "Psychiatric comorbidities". In Psoriasis, 167–72. Second edition. | Boca Raton, FL : CRC Press, Taylor & Francis Group, [2017] | Preceded by Psoriasis / Alan Menter, Benjamin Stoff. c2011.: CRC Press, 2017. http://dx.doi.org/10.1201/9781315119298-17.
Testo completo
2
Mahmood, Syed Hazique. "Psychiatric Comorbidities and Treatments". In Pain Medicine, 209–12. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-43133-8_59.
Testo completo
3
Jim Anthony, James C. "Understanding Psychiatric Comorbidities and Addictions". In The Wiley-Blackwell Handbook of Addiction Psychopharmacology, 83–109. Oxford, UK: Wiley-Blackwell, 2013. http://dx.doi.org/10.1002/9781118384404.ch4.
Testo completo
4
Thames, April D., e Jacob D. Jones. "Psychiatric Comorbidities in HIV Infection". In Global Virology II - HIV and NeuroAIDS, 283–313. New York, NY: Springer New York, 2017. http://dx.doi.org/10.1007/978-1-4939-7290-6_12.
Testo completo
5
Jenkins, James A. "Psychiatric Comorbidities and Appropriate Psychopharmacology". In Borderline Personality Disorder, 125–35. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-90743-7_11.
Testo completo
6
Serafini, Gianluca, Shuu-Jiun Wang, Dorian Lamis, Martina Curto, Paolo Girardi, Mario Amore e Maurizio Pompili. "Psychiatric Comorbidity in Migraine and Chronic Headache". In Comorbidities in Headache Disorders, 23–40. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-41454-6_2.
Testo completo
7
Arruda, Marco A., Noemi Faedda, Giulia Natalucci e Vincenzo Guidetti. "Comorbidity with Psychiatric Disorders". In Headache and Comorbidities in Childhood and Adolescence, 125–34. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-54726-8_12.
Testo completo
8
Collins, Robert L., Hannah L. Combs, Shannon R. Miles, Nicholas J. Pastorek, Andra Teten Tharp e Thomas A. Kent. "Behavioral and Psychiatric Comorbidities of TBI". In Traumatic Brain Injury, 239–61. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-22436-3_14.
Testo completo
9
Collins, Robert L., Nicholas J. Pastorek, Andra T. Tharp e Thomas A. Kent. "Behavioral and Psychiatric Comorbidities of TBI". In Traumatic Brain Injury, 223–44. New York, NY: Springer New York, 2012. http://dx.doi.org/10.1007/978-0-387-87887-4_13.
Testo completo
10
Ameis, Stephanie H., e Peter Szatmari. "Common psychiatric comorbidities and their assessment". In Clinician’s Manual on Autism Spectrum Disorder, 19–32. Cham: Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-03056-2_3.
Testo completoAtti di convegni sul tema "Psychiatric comorbidities"
1
Perera, SJ. "G623 Non psychiatric comorbidities in adhd: a scoping exercise". In Royal College of Paediatrics and Child Health, Abstracts of the RCPCH Conference–Online, 25 September 2020–13 November 2020. BMJ Publishing Group Ltd and Royal College of Paediatrics and Child Health, 2020. http://dx.doi.org/10.1136/archdischild-2020-rcpch.537.
Testo completo
2
Uribe, J. P., A. Ayala, M. Carreiro, D. Ospina-Delgado, F. Kheir, S. Gangadharan, J. Wilson, M. S. Parikh, A. C. Chee e A. Majid. "Medical and Psychiatric Comorbidities in Excessive Central Airway Collapse: A High-Volume, Single Center Experience". In American Thoracic Society 2020 International Conference, May 15-20, 2020 - Philadelphia, PA. American Thoracic Society, 2020. http://dx.doi.org/10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a6871.
Testo completo
3
Faraguna, U., C. Porciani, R. Vagelli, M. di Galante, C. Tani, C. Stagnaro e M. Mosca. "PS6:118 Objective measurements of sleep disorders and psychiatric comorbidities in a cohort of patients with systemic lupus erythematosus". In 11th European Lupus Meeting, Düsseldorf, Germany, 21–24 March 2018, Abstract presentations. Lupus Foundation of America, 2018. http://dx.doi.org/10.1136/lupus-2018-abstract.161.
Testo completo